A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects

NCT06422624 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests the safety, tolerability, and how the body processes a long-acting injectable form of semaglutide in healthy adults.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 14 people Planned (estimated).

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2024-08 · est. completion 2024-11

What this study is testing ClinicalTrials.gov NCT06422624 ↗

Description as written by the study sponsor.

The purpose of the trail is to evaluate the safety, tolerability and pharmacokinetics of a single escalated doses of semaglutide extended-release injectable suspension in healthy adult, human study participants under fasting condition.

Treatments tested

Semaglutide Extended-release for Injectable Suspension, 1 mg Drug

Singel-dose; Subcutaneous
Semaglutide Extended-release for Injectable Suspension, 4 mg Drug

Singel-dose; Subcutaneous
Semaglutide Extended-release for Injectable Suspension, 8 mg Drug

Singel-dose; Subcutaneous

Main thing measured	Cmax
Sponsor	Bostal Drug Delivery Co., Ltd
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06422624 ↗